With rival to anti-TNF injectables, Protalix reports positive PhII data in ulcerative colitis
An Israeli biotech looking to make a pill that would replace anti-TNF injectables — a multibillion dollar market — today reported good news from its small Phase II study in ulcerative colitis.
The company, called Protalix, says its therapy met the key efficacy endpoints of the trial. The drug is a recombinant human tumor necrosis factor receptor II fused to an IgG1 Fc domain. Protalix says the therapy, called OPRX-106, is biologically active in the gut without triggering the formation of anti-drug antibodies — a key factor in the failure of anti-TNF treatments thus far.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
